摘要
目的观察口服DDAVP片剂 (商品名弥凝 )治疗中枢性尿崩症的疗效。 方法单剂量试验 ,即比较单次口服弥凝 0 .1mg前后尿量、尿渗透压等指标的变化 ;两周试验 ,即观察弥凝 0 .0 5～ 0 .2mg ,2～ 4次 /d口服的疗效。结果单次口服弥凝 0 .1mg后 ,尿量迅速下降为服药前的 1/ 10 ,尿渗透压上升为服药前 10倍。此作用维持 4～ 2 0h。服药两周后 ,尿量控制 ,较前减少 (72 .6± 6 .6 ) %。血渗透压下降达 2 92± 10mOsm/kg (1mOsm =2 5 73Pa)。用药期间无一例有不良反应。 结论口服弥凝 (DDAVP片剂 )治疗中枢性尿崩症安全方便。
Objective To observe the efficacy of oral DDAVP(minirin) in patients with central diabetes insipidus. Methods Changes in the urine volume and osmolality after one single dose of minirin( 0.1mg) and after two weeks of minirin medication (0.05 ～ 0.2mg,2 ～ 4times each day)were observed in 10 patients. Results The urine volume reduced significantly and urine osmolality increased after a single dose of minirin (0.1mg),and this action lasted 4 ～ 20h. After two weeks of minirin therapy,the urine volume decreased (72.6±6.6)%, and plasma osmolality decreased to 292±10mOsm/kg
出处
《上海第二医科大学学报》
CSCD
2002年第1期61-63,共3页
Acta Universitatis Medicinalis Secondae Shanghai
